Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of various autoimmune and other diseases in 2015.
The deal was worth a potential $690 million in total but that hasn’t stopped Lilly showing every sign of ducking out of the deal early.
